Zobrazeno 61 - 70
of 13 227
pro vyhledávání: ''
Autor:
Panpan Han, Jun Peng, Guosheng Li, Yu Hou, Yang Liu, Haoyi Wang, Yunqi Sun, Tianshu Yu, Hai Zhou, Ming Hou, Xinguang Liu, Lizhen Li, Yajing Zhao, Pengcheng Xu, Xiang Hu, Tao Sun
Publikováno v:
Blood. 138:674-688
Our previous clinical study showed that low-dose decitabine exhibited sustained responses in nearly half of patients with refractory immune thrombocytopenia (ITP). The long-term efficacy of decitabine in ITP is not likely due to its simple role in in
Autor:
S R Abd El-Khalik, M A Elsebaey, Marwa Mohamed Atef, Sherif Abd-Al Fattah Saber, Yasser Mostafa Hafez, Alaa I. Amer
Publikováno v:
British Journal of Biomedical Science. 78:122-129
BACKGROUND Colorectal cancer is one of the most common cancers worldwide and a major cause of cancer-related death. Thus molecular biomarkers for colorectal cancer have been proposed. The role of long non-coding RNA EGFR-AS1 in colorectal cancer is s
Publikováno v:
Cancer Immunology, Immunotherapy
Transurethral resection of the tumor (TUR-B) followed by adjuvant intravesical treatment with cytostatic drugs or Bacillus Calmette–Guérin (BCG) as standard therapy of non-muscle-invasive bladder cancer (NMIBC) is associated with a high recurrence
Autor:
Yaojun Zhang, Ming Shi, Zhi-Cheng Lai, Min-Ke He, Run-Bin Liang, Wei Wei, Chuan Peng, Qi-Jiong Li, Rong Ping Guo, Anna Kan, Minshan Chen, Yang Zhao
Publikováno v:
Cancer Immunology, Immunotherapy. 70:3207-3216
Programmed cell death protein-1 (PD-1) inhibitor is recommended to treat advanced hepatocellular carcinoma (HCC). However, the safety of PD-1 inhibitor in patients with high HBV-DNA load is unknown because of the potential risk of hepatitis B virus (
Autor:
Jürgen C. Becker, Stephan Grabbe, Ulrike Leiter, Henner Stege, Claudia Pföhler, Peter Mohr, Jessica C. Hassel, Carmen Loquai, S. Schultheis, Felix Kiecker, S. Ugurel, Maximilian Haist, Patrick Terheyden, Markus Meissner, Maria Isabel Fleischer, J. Kleeman, A. Thiem
Publikováno v:
Cancer Immunology, Immunotherapy
Background Immune checkpoint inhibitors (ICI) have led to a prolongation of progression-free and overall survival in patients with metastatic Merkel cell carcinoma (MCC). However, immune-mediated adverse events due to ICI therapy are common and often
Autor:
William Rodin, Filip Ahlmanner, Elinor Bexe Lindskog, Yvonne Wettergren, Louis Szeponik, Kamil Kajetan Zajt, Marianne Quiding Järbrink, Patrik Sundström
Publikováno v:
Cancer Immunology, Immunotherapy
Mucosal-associated invariant T (MAIT) cells are unconventional T cells recognizing microbial metabolites, presented by the invariant MR1 protein. Upon activation, MAIT cells rapidly secrete cytokines and exert cytotoxic functions, and may thus be hig
Autor:
Masanori Hayashi, Tetsuro Yamagishi, Chihaya Imai, Hajime Umezu, Takashi Ariizumi, Yudai Murayama, Akira Ogose, Naoki Oike, Hiroyuki Kawashima, Hiroshi Hatano, Naoto Endo
Publikováno v:
Cancer Immunology, Immunotherapy
The characteristics of the tumor immune microenvironment remains unclear in liposarcomas, and here we aimed to determine the prognostic impact of the tumor immune microenvironment across separate liposarcomas subtypes. A total of 70 liposarcoma patie
Autor:
Hideki Ueno, Chigusa Morizane, Shuichi Mitsunaga, Masafumi Ikeda, Yasunori Ushida, Kazuto Gemmoto, Shunsuke Kondo, Takuji Okusaka, Hideaki Suna, Junji Furuse, Izumi Ohno
Publikováno v:
Immunotherapy. 13:371-385
Aim: Two peptide cocktail vaccines using glypican-3, WD-repeat-containing protein up-regulated in hepatocellular carcinoma (HCC) and nei endonuclease VIII-like three epitopes were evaluated in advanced HCC in two Phase I studies. Patients & methods:
Publikováno v:
Cancer Immunol Immunother
BACKGROUND: Immune checkpoint inhibitors (ICI) blocking inhibitory immune pathways (e.g., programmed cell death protein-1/-ligand1 [PD-1/PD-L1]) have revolutionized cancer therapy for numerous malignancies. There have been an increasing number of cas
Autor:
Hideo Yagita, Linan Wang, Eiichi Sato, Yoshito Itoh, Tetsuya Okayama, Shinichi Kageyama, Takeshi Ishikawa, Satoshi Kokura, Hiroshi Shiku, Yoshihiro Miyahara
Publikováno v:
Cancer Immunology, Immunotherapy. 70:3081-3091
The nanoparticle complex of cholesteryl pullulan (CHP) and NY-ESO-1 antigen protein (CHP-NY-ESO-1) presents multiple epitope peptides to MHC class I and II pathways, leading to CD8+ and CD4+ T cell responses. Poly-ICLC is a synthetic, double-stranded